VKT_MACLN
ID VKT_MACLN Reviewed; 95 AA.
AC I2G9B4;
DT 01-MAY-2013, integrated into UniProtKB/Swiss-Prot.
DT 11-JUL-2012, sequence version 1.
DT 25-MAY-2022, entry version 22.
DE RecName: Full=Kunitz-type serine protease inhibitor PIVL;
DE Flags: Precursor;
OS Macrovipera lebetina transmediterranea (Blunt-nosed viper) (Vipera lebetina
OS transmediterranea).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Lepidosauria; Squamata; Bifurcata; Unidentata; Episquamata; Toxicofera;
OC Serpentes; Colubroidea; Viperidae; Viperinae; Macrovipera.
OX NCBI_TaxID=384075;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBUNIT, PYROGLUTAMATE FORMATION AT
RP GLN-25, AND MASS SPECTROMETRY.
RC TISSUE=Venom, and Venom gland;
RX PubMed=23262217; DOI=10.1016/j.matbio.2012.11.015;
RA Morjen M., Kallech-Ziri O., Bazaa A., Othman H., Mabrouk K.,
RA Zouari-Kessentini R., Sanz L., Calvete J.J., Srairi-Abid N., El Ayeb M.,
RA Luis J., Marrakchi N.;
RT "PIVL, a new serine protease inhibitor from Macrovipera lebetina
RT transmediterranea venom, impairs motility of human glioblastoma cells.";
RL Matrix Biol. 32:52-62(2013).
CC -!- FUNCTION: Serine protease inhibitor that inhibits trypsin. Exhibits an
CC anti-tumor effect and displays integrin inhibitory activity without
CC being cytotoxic. Is able to dose-dependently inhibit the adhesion,
CC migration and invasion of human glioblastoma U87 cells. Also impairs
CC the function of alphavbeta3 and to a lesser extent, the activity of
CC alphavbeta6, alphavbeta5, alpha1beta1 and alpha5beta1 integrins.
CC {ECO:0000269|PubMed:23262217}.
CC -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:23262217}.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Expressed by the venom gland.
CC -!- MASS SPECTROMETRY: Mass=7691.7; Method=MALDI; Note=Average mass.;
CC Evidence={ECO:0000269|PubMed:23262217};
CC -!- MISCELLANEOUS: Does not inhibit chymotrypsin.
CC {ECO:0000305|PubMed:23262217}.
CC -!- MISCELLANEOUS: When intracerebroventricularly injected into mice, does
CC not cause any toxic symptoms until a dose of 2 ug.
CC {ECO:0000305|PubMed:23262217}.
CC -!- SIMILARITY: Belongs to the venom Kunitz-type family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; HE800183; CCH15044.1; -; mRNA.
DR AlphaFoldDB; I2G9B4; -.
DR SMR; I2G9B4; -.
DR MEROPS; I02.062; -.
DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; IEA:UniProtKB-KW.
DR CDD; cd00109; KU; 1.
DR Gene3D; 4.10.410.10; -; 1.
DR InterPro; IPR002223; Kunitz_BPTI.
DR InterPro; IPR036880; Kunitz_BPTI_sf.
DR InterPro; IPR020901; Prtase_inh_Kunz-CS.
DR Pfam; PF00014; Kunitz_BPTI; 1.
DR PRINTS; PR00759; BASICPTASE.
DR SMART; SM00131; KU; 1.
DR SUPFAM; SSF57362; SSF57362; 1.
DR PROSITE; PS00280; BPTI_KUNITZ_1; 1.
DR PROSITE; PS50279; BPTI_KUNITZ_2; 1.
PE 1: Evidence at protein level;
KW Disulfide bond; Protease inhibitor; Pyrrolidone carboxylic acid; Secreted;
KW Serine protease inhibitor; Signal.
FT SIGNAL 1..24
FT CHAIN 25..91
FT /note="Kunitz-type serine protease inhibitor PIVL"
FT /id="PRO_0000422086"
FT PROPEP 92..95
FT /id="PRO_0000422087"
FT DOMAIN 31..81
FT /note="BPTI/Kunitz inhibitor"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00031"
FT REGION 65..67
FT /note="Responsible for the anti-cancer effect"
FT SITE 41..42
FT /note="Reactive bond"
FT /evidence="ECO:0000250"
FT MOD_RES 25
FT /note="Pyrrolidone carboxylic acid"
FT /evidence="ECO:0000269|PubMed:23262217"
FT DISULFID 31..81
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00031"
FT DISULFID 40..64
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00031"
FT DISULFID 56..77
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00031"
FT VARIANT 67
FT /note="N -> S"
SQ SEQUENCE 95 AA; 10569 MW; CF3FE5D9C82B97F7 CRC64;
MSSGGLLLLL GLLTLWAELT PVSSQDRPKF CYLPADPAEC NAYMPRFYYD SASNKCKEFI
YGGCRGNANN FKNRAECRHT CVASRKGIQP RIASN